The Measurement Playbook: What to Track When Evaluating Your Preventive Care Investment

If you’ve ever presented healthcare cost data to your leadership team only to have it picked apart—“Does this account for the fact that healthier people are more likely to participate?” or “What about the employee who had a $700,000 cancer claim?”—you already understand why methodology matters.

The data behind preventive care outcomes is abundant. Claims databases, utilization records, biometric screenings, and employee surveys generate enormous volumes of information. The problem isn’t scarcity. It’s credibility. An evaluation that doesn’t address obvious biases—selection effects, demographic differences, outlier costs—will be dismissed by the very stakeholders you’re trying to convince.

This article outlines the analytical playbook for evaluating preventive primary care in a way that produces results your CFO, your board, and your consultants will trust.

Why “Gold Standard” Studies Don’t Work for Employer Programs

In clinical research, the randomized controlled trial sits at the top of the evidence hierarchy. You randomly assign people to an intervention group or a control group, follow them over time, and compare the results. Randomization removes most of the biases that make it hard to determine whether differences in outcomes are caused by the program or by pre-existing differences between the groups.

Employer-sponsored health programs almost never have the luxury of randomization. You can’t tell half your workforce they’re not allowed to participate in the preventive care benefit. The cost and time involved are prohibitive. And in practice, the people who sign up for a preventive program are often different—demographically, clinically, motivationally—from those who don’t.

This is why most employers rely on retrospective cohort studies: looking backward at how participants and non-participants differed on key outcomes. It’s a practical approach, but it comes with a critical caveat. Without additional steps to control for the differences between these groups, the results can be misleading. A finding that “program participants had lower costs” might simply mean that healthier, lower-cost employees were the ones who participated in the first place.

The methodology that follows is designed to address exactly this problem.

Defining the Right Cohorts

The foundation of a credible evaluation is defining who you’re comparing. In the context of a preventive care program, three cohorts are typically used: adults who had a preventive visit through the program, adults who had a preventive visit through another provider, and adults who did not have a preventive exam at all during the measurement period.

That three-way comparison is important. A common mistake is comparing only program participants to everyone else. But “everyone else” includes both people who sought preventive care elsewhere and people who avoided it entirely—two very different populations with very different risk profiles and cost patterns. Separating them gives you a more granular and more honest picture.

Once the cohorts are defined, three inclusion and exclusion criteria need careful attention.

Eligibility

Not every employee may be eligible for the program. Including ineligible employees in the non-participant group inflates that group’s apparent costs or understates them, depending on why they were excluded. Clean your comparison set by removing anyone who wasn’t eligible to participate.

High-cost Claimants

A single employee with a catastrophic illness can incur more than $1 million in claims in a single year. Even one such case in a small cohort can overwhelm the entire analysis, making it impossible to detect real trends. Most analytical platforms can accommodate this by running results both with and without high-cost claimants—a step that should be standard practice in any evaluation.

Tenure on plan

Preventive care delivers value on different timescales. An avoided ER visit is a near-term benefit. A cancer caught at Stage I instead of Stage III plays out over years. To capture both types of impact, the analysis should include individuals with continuous plan eligibility for at least 12 months, and ideally 24 months. Someone who uses the program in March and leaves the company in May won’t generate enough data to be meaningful in either direction.

[GRAPHIC: Flowchart showing how a total employee population of 10,000 gets filtered into the three cohorts, with exclusion criteria applied at each stage. Should visually demonstrate the narrowing process and make clear why each exclusion matters.]

The Selection Bias Problem—and How to Solve It

Defining cohorts and setting inclusion criteria won’t fully solve for the demographic and clinical differences between groups. This is the “healthy user” problem that critics of wellness programs have pointed to for years: people who voluntarily sign up for preventive care tend to be healthier, younger, or more health-conscious than those who don’t. If you don’t adjust for this, you’re essentially comparing apples to oranges and calling it evidence.

Several adjustment methods exist, ranging from basic to sophisticated. At the simplest level, normalizing results by age and sex distribution corrects for the most obvious demographic skews. More rigorous approaches use third-party risk adjusters that analyze claims data to quantify the illness burden in each cohort. The most advanced technique, propensity score matching, uses statistical methods to construct an artificial control group that mirrors the participant group on observable characteristics.

The point isn’t that every employer needs the most sophisticated technique. The point is that accepting raw cohort comparisons at face value is the fastest way to produce findings that don’t hold up. At minimum, age/sex adjustment should be applied. For larger employers or higher-stakes evaluations, risk adjustment or propensity matching is worth the investment—because the findings will carry far more weight with skeptical finance teams and consultants.

[GRAPHIC: Before/after comparison showing how risk adjustment changes the cost comparison between cohorts. Left side: “Unadjusted” showing participant costs 15% lower. Right side: “Risk-Adjusted” showing participant costs 11% lower—still significant, but more credible. Include note: “Risk adjustment removes healthy-user bias, producing results that survive scrutiny.”]

Tracking Health Status Over Time

Financial and utilization measures tell you whether a program is saving money. Health status measures tell you whether it’s actually improving health—and whether those improvements are likely to sustain cost savings over the long term.

Various approaches are available, depending on what data you can access. Risk adjuster trends show whether illness burden is increasing or decreasing across your cohorts. Chronic condition tracking identifies whether individuals with diabetes, hypertension, cardiovascular risk factors, and other conditions are improving, stable, or deteriorating. When lab data and biometrics are available—blood pressure, cholesterol, A1C levels—they provide the most direct evidence of whether the program is moving the needle.

This data may not be equally available across all cohort groups, but it remains valuable for tracking changes within the participant population over time. Even if you can’t make a perfect comparison to non-participants, demonstrating that your program participants are trending in the right direction on key health indicators builds a powerful narrative alongside the financial data.

Who Does All This Work?

The analytical methodology described above might sound daunting, but the operational requirements are manageable. What it takes is partnership: the program vendor provides participation data and clinical information, medical and pharmacy carriers supply the claims data (or a data warehouse, when available), and analytical expertise can come from any of these organizations, from the employer’s consultant, or from specialized firms.

The critical success factor isn’t analytical sophistication—it’s commitment. All parties need to agree upfront to share the data required and to follow sound methods. Most evaluation studies of the type described here can be completed in 8 to 12 weeks once all data is available. That’s not a multi-year research project. It’s a focused effort that produces credible, actionable results.

The employers who are best positioned are those whose program partners are committed to transparency and accountability. If your preventive care vendor isn’t willing to subject their outcomes to rigorous, independent evaluation, that tells you something important about the outcomes.

From Measurement to Confidence

The gap between “I think prevention is valuable” and “I can prove prevention reduces our healthcare costs” is a methodology gap. The data is available. The frameworks are well-established. The analytical tools are not out of reach. What’s required is a commitment to defining the right cohorts, adjusting for the biases that make raw comparisons unreliable, tracking the right measures across cost, utilization, quality, experience, and health status—and partnering with vendors who welcome that level of scrutiny.

That’s not just how you justify a budget line item. It’s how you build the foundation for a healthcare strategy that your organization can trust for years to come.

For the complete analytical framework—including detailed guidance on study design, financial measure selection, and health status tracking—download the full white paper: Measuring the Impact of Preventive Primary Care.